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Key  points  
  
•   Deletion  of  both  Rap1a  and  Rap1b  impairs  platelet  production  and  abolishes  platelet  
adhesion  at  sites  of  mechanical  trauma.  
•   Platelet  RAP1  signaling  is  dispensable  for  vascular  integrity  during  development  and  






RAP   GTPases,   important   regulators   of   cellular   adhesion,   are   abundant   signaling  
molecules  in  the  platelet/megakaryocytic  lineage.  However,  mice  lacking  the  predominant  
isoform,  RAP1B,  display  a  partial  platelet   integrin  activation  defect  and  have  a  normal  
platelet   count,   suggesting   the   existence   of   a   RAP1-­independent   pathway   to   integrin  
activation  in  platelets  and  a  negligible  role  for  RAP  GTPases  in  megakaryocyte  biology.  
To  determine   the   importance  of   individual  RAP   isoforms  on  platelet  production  and  on  
platelet   activation   at   sites   of   mechanical   injury   or   vascular   leakage,   we   conditionally  
deleted   Rap1a   and/or   Rap1b   in   the   megakaryocytic   lineage   (mKO).   Interestingly,  
Rap1a/b-­mKO  mice   displayed   a  marked  macrothrombocytopenia  due   to   impaired  pro-­
platelet  formation  by  megakaryocytes.  In  platelets,  RAP  isoforms  had  both  redundant  and  
isoform-­specific   functions.  Deletion  of  RAP1B,  but  not  RAP1A,  significantly   reduced  α-­
granule   secretion   and   activation   of   the   cytoskeleton   regulator   RAC1.   Both   isoforms  
significantly   contributed   to   thromboxane  A2   generation   and   the   inside-­out   activation   of  
platelet  integrins.  Combined  deficiency  of  RAP1A  and  RAP1B  markedly  impaired  platelet  
aggregation,   spreading   and   clot   retraction.   Consistently,   thrombus   formation   in  
physiological   flow   conditions   was   abolished   in  Rap1a/b-­mKO,   but   not   Rap1a-­mKO  or  
Rap1b-­mKO  platelets.  Rap1a/b-­mKO  mice   were   strongly   protected   from   experimental  
thrombosis   and   exhibited   a   severe   defect   in   hemostasis   after   mechanical   injury.  
Surprisingly,  Rap1a/b-­mKO  platelets  were  indistinguishable  from  controls  in  their  ability  to  
prevent   blood-­lymphatic   mixing   during   development   and   hemorrhage   at   sites   of  
inflammation.    
In   summary,   our   studies   demonstrate   an   essential   role   for   RAP1   signaling   in   platelet  
integrin   activation   and   a   critical   role   in   platelet   production.   While   important   for  
hemostatic/thrombotic  plug  formation,  platelet  RAP1  signaling  is  dispensable  for  vascular  
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Introduction  
Platelets   are   specialized   cells   generated   from   the   cytoplasmic   fragmentation   of  
megakaryocytes  to  ensure  the  integrity  of  the  vascular  system  upon  mechanical  injury  or  
any   other   vascular   breach,   occurring   for   instance   at   sites   of   inflammation1-­3.   Platelet  
stimulation  triggers  intracellular  signaling  cascades  that  promote  cytoskeletal  remodeling,  
secretion  of  granules,  release  of  eicosanoids,  and  conversion  of  integrin  receptors  from  a  
low-­   to  high-­affinity  state   for   their   ligands   (inside-­out  activation).  Once  active,   integrins  
mediate  platelet  adhesion  to  the  exposed  extracellular  matrix  and  aggregation  to  adjacent  
active   platelets.   Auto/paracrine   agonists   released   from   activated   platelets,   such   as  
adenosine   diphosphate   (ADP)   and   thromboxane   (Tx)   A2,   locally   perpetuate   platelet  
activation  and  promote  the  formation  of  a  stable  shear-­resistant  hemostatic  plug4,5.  
The  signaling  machinery  controlling  these  responses  must  be  tightly  regulated  to  prevent  
pathological  thrombosis  or  bleeding.  RAP  GTPases  (Ras-­related  proteins)  are  among  the  
most  abundant  signaling  proteins  expressed  in  platelets6-­9.  They  are  molecular  switches  
that  cycle  between  a  GDP-­bound  OFF  state  and  a  GTP-­bound  ON  state,  under  the  tight  
control  of  guanine-­nucleotide  exchange  factors  (GEFs)  and  GTPase  activating  proteins  
(GAPs)10.  Once  GTP-­loaded,  RAP  GTPases  undergo  conformational  changes  that  enable  
specific   binding   to  effectors,  which   in   turn   control   a  wide   range  of  biochemical   events,  
most   notably   cell   adhesion11,   cytoskeletal   dynamics12   and   mitogen-­activated   protein  
kinase  (MAPK)  cascades13.    
Vertebrates  express   two  RAP1  and  three  RAP2  isoforms  encoded  by  separate  genes.  
Rap1a   and   Rap1b   share   a   95%   sequence   identity,   suggesting   that   they   may   have  
redundant  functions  during  cellular  activation.  However,   there   is  also  growing  evidence  
that   these   two  closely-­related   isoforms  differentially   regulate   cellular   functions   such  as  
NADPH  oxidase  activity14,15  and  cadherin-­mediated  adhesion16.  In  platelets,  RAP1A  and  
RAP1B  are  the  most  highly  expressed  members  of  the  RAS  superfamily6-­9.  Our  previous  
studies  demonstrated  that  both  the  activity  state  of  RAP1  and  platelet  adhesiveness  are  
controlled   by   the   antagonistic   balance   between   two   upstream   RAP   regulators17,18.   In  
circulating  platelets,  RAP  proteins  are  maintained  inactive  by  the  RAP-­GAP  RASA318.  At  
sites  of  injury,  when  platelets  are  stimulated,  the  RAP-­GEF  CalDAG-­GEFI  mediates  rapid  
RAP   activation   triggered   by   the   near-­immediate   rise   of   cytosolic   calcium  
concentrations17,19-­21;;  however,  this  response  is  transient  in  nature  and  RAP  can  quickly  
reverse  back  to  the  OFF  state.  Thus,  signaling  from  secreted  ADP  via  the  P2Y12  receptor  
is  critical  to  inactivate  RASA3  and  enable  sustained  RAP  activation18,22.  Simultaneous  loss  
of  both  RAP  stimulatory  pathways  leads  to  marked  defects  in  integrin  activation22,  RAC1-­
mediated  cytoskeletal  dynamics  20,23,  MAPK  ERK  signaling  and  TxA2  generation19.  
These  studies  provide  indirect  evidence  that  RAP  signaling   is  critical   for  overall  platelet  
activation   and   hemostatic   plug   formation.   The   only   direct   evidence   supporting   an  
important  role  for  RAP1  signaling   in  platelet  activation  comes  from  studies   in  mice  with  
systemic   deletion  of   the  predominant  RAP1   isoform   in   platelets,   RAP1B.   Surprisingly,  
Rap1b-­/-­  platelets  displayed  a  rather  mild  platelet  phenotype,  including  partially  decreased  
agonist-­induced   fibrinogen   binding   and   aggregation24,   reduced   cytoskeleton-­regulated  
responses  such  as  secretion  and  spreading,  and  no  defect  in  MAPK  signaling25.  To  date,  
the  role  of  RAP1A  in  the  platelet  hemostatic  response  has  not  been  resolved,  although  
Chrzanowska-­Wodnicka  and  colleagues  reported  unpublished  observations  that  platelet  
aggregation  is  normal  in  RAP1A-­null  mice24.  Mice  lacking  RAP1A  have  impaired  immune  
cell  functions,  which  were  not  compensated  for  by  RAP1B,  suggesting  that  these  isoforms  
may  indeed  have  distinct  roles26.  Interestingly,  the  peripheral  platelet  count  and  size  was  
normal   in  Rap1a-­/-­   and  Rap1b-­/-­  mice,   suggesting  a  minimal   role   for  RAP1  signaling   in  
platelet  production.  This  finding  is  surprising  considering  that  RAP1  GTPases  are  highly  
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expressed  in  platelet  progenitor  cells27.  However,  very  little28,29  has  been  done  so  far  to  
investigate  their  role  in  megakaryocyte  biology  and  platelet  production.  
In  the  present  study,  we  characterized  mice  with  targeted  deletion  of  Rap1a  and  Rap1b  
selectively  in  the  platelet/megakaryocyte  lineage  to  investigate  the  specific  contribution  of  
the  individual  RAP  isoforms  in  the  regulation  of  platelet  production,  platelet  activation  and  
hemostatic/thrombotic   plug   formation.   We   demonstrate   that   RAP   isoforms   have   both  
redundant  and  isoform-­specific   functions   in  platelets  and  that  they  are  essential   for   the  
regulation   of   hemostasis   at   sites   of   mechanical   injury,   but   dispensable   at   sites   of  





Generation  of  Rap1afl/flRap1bfl/fl  30   and  Talin1fl/fl31  mice     has  been  described  previously.  
Megakaryocyte-­specific  Rap1a  knockout  (Rap1a-­mKO),  Rap1b  knockout  (Rap1b-­mKO),  
Rap1a/b  double  knockout  mice   (Rap1a/b-­mKO)  and   their   respective  control  mice  were  
generated   by   crossing   Rap1afl/flRap1bfl/fl   mice   with   C57BL/6-­Tg(Pf4-­Cre+)   mice32.  




Proplatelet   formation  was   studied   in  mouse  bone  marrow–derived  megakaryocytes  as  
described  recently18.    
  
Platelet  studies  
Platelet  count,  size  and  lifespan,  surface  receptor  expression,   integrin  αIIbβ3  activation  
and  α-­granule  secretion  were  determined  as  previously  described18.  Integrin  β1  activation  
was  determined  by  measuring  the  binding  of  an  antibody  directed  against  the  active  form  
of  murine  β1  (clone  9EG7)33.  Aggregometry  and  RAP2  pull-­down  assays  were  performed  
as  described  in  23.  Ex  vivo  flow  studies  were  performed  in  a  collagen-­coated  microfluidic  
chamber  as  described  in  22.  
  
Thrombosis  and  hemostasis  studies  
Ferric  chloride(FeCl3)-­induced  thrombosis  to  the  common  carotid  artery  was  performed  as  
described   previously34.   Tail   bleeding   time   and   blood   loss   volume   were   measured   as  
described  in22.  Hemostatic  plug  formation  and  bleeding  time  upon  laser-­induced  injury  to  
the  saphenous  vein  was  described  in  35.    
  
Vascular  integrity  studies  
The  contribution  of  platelets  to  vascular  integrity  at  sites  of  inflammation  was  determined  
by   challenging   mice   with   the   reverse   passive   Arthus   (rpA)   reaction   as   described  
previously36.   Preparation   and   immunohistochemistry   of   embryos   at   ~E16.5   to   assess  
blood-­lymphatic  mixing  (BLM)  was  performed  as  described  in  18.    
  
Statistics  
Results   are   reported   as   mean   ±   standard   error   of   the   mean   (SEM)   and   statistical  
significance  was  assessed  by  ANOVA   test,  unless  otherwise   indicated.  A  P  value   less  
than  0.05  was  considered  significant.  
  
Detailed  methods  are  presented  in  the  online  supplement.  
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Results  
Combined  deficiency  of  RAP1A  and  RAP1B  in  the  platelet/megakaryocytic  lineage  
leads  to  macrothrombocytopenia.  
Systemic   deletion   of   both   RAP1   isoforms   is   not   viable   in   mice37.   To   investigate   the  
respective  role  of  RAP1A  and  RAP1B  in  platelet  biology,  we  crossed  floxed  Rap1a  and  
Rap1b  mice30  with  C57BL/6-­Tg(Pf4-­Cre)  mice32,  where  the  Cre  recombinase  expression  
is   driven  by   the  Pf4   promoter.  Megakaryocyte-­specific  Rap1a/b   double   knockout  mice  
(Rap1a/b-­mKO,  Rap1afl/flRap1bfl/flPf4-­Cre+)  were  viable  and  fertile  and  appeared  overall  
healthy,  with  no  spontaneous  bleeding  seen   to  date.  Mice  were   routinely  genotyped   to  
detect  the  floxed  Rap1  alleles  and  the  Cre  recombinase  gene  (Supplementary  Figure  
1A).  Western  blot  analysis  confirmed  the  complete  ablation  of  both  RAP1  isoforms  in  the  
Rap1a/b-­mKO   platelets   and   deletion   of   RAP1A   or   RAP1B   in   Rap1a-­mKO  
(Rap1afl/flRap1b+/+Pf4-­Cre+)   and   Rap1b-­mKO   (Rap1a+/+Rap1bfl/flPf4-­Cre+)   mice,  
respectively   (Supplementary   Figure   1B).   Both   platelet   count   and   platelet   size   were  
normal   in  Rap1a-­mKO   mice   (data   not   shown).   Rap1b-­mKO   mice   exhibited   a   normal  
platelet  count  and  a  slight  increase  in  platelet  size  (Figure  1A,B).  Concomitant  deletion  of  
one  allele  of  Rap1a  led  to  a  further  increase  in  platelet  size  (Figure  1B).  Rap1a/b-­mKO  
displayed  a  ~40%  reduction   in  platelet  count  and  a  ~50%  increase  in  platelet  size.  The  
marked  thrombocytopenia  observed  in  Rap1a/b-­mKO  mice  is  likely  the  result  of  impaired  
platelet  production,  as  we  observed  no  reduction,  but  rather  a  slight  increase,  in  the  half-­
life   of   Rap1a/b-­mKO   platelets   in   circulation   (Figure   1C)   and   a   significant   defect   in  
proplatelet  formation  by  megakaryocytes  ex  vivo  (Figure  1D,E).    
  
Signaling  by  both  RAP1A  and  RAP1B  contributes  to  platelet  integrin  activation.  
Given  the  documented  role  of  RAP1  signaling  in  cell  adhesion11,  we  next  investigated  the  
role  of  both  RAP1  isoforms  in  integrin  activation.  Deletion  of  both  isoforms  did  not  impair  
the  surface  expression  of  important  adhesion  receptors,  including  αIIbβ3  and  β1  integrins  
(Supplementary   Figure   1C).   Agonist-­induced   activation   of   platelet   integrins   was   first  
evaluated   by   flow   cytometry   using   conformation-­sensitive   antibodies   against   activated  
αIIbβ3  (Figure  2A)  and  β1  (Figure  2B).  Consistent  with  studies   in  conventional  Rap1b  
knockout   mice24,   integrin   activation   was   partially   reduced   in   Rap1b-­mKO   platelets  
activated  with  various  agonists.  A  more  modest,  but  significant  defect  in  integrin  activation  
was  observed  in  Rap1a-­mKO  platelets,  revealing  a  previously  unrecognized  role  for  this  
isoform  in  platelet   inside-­out  signaling.   Importantly,  combined  deficiency  of  RAP1A  and  
RAP1B  led  to  an  almost  complete  (80-­90%)  inhibition  of  αIIbβ3  and  β1  integrin  activation,  
even  at  high  doses  of  strong  agonists.    
  
Limited  integrin  activation,  mediated  by  TALIN1,  in  platelets  lacking  both  RAP1  
isoforms  is  not  mediated  by  RAP2  GTPases.    
TALIN   binding   to   the   integrin   β   tail   is   the   final   common   step   that   mediates   integrin  
activation.   Elegant   studies   in   heterologous   cell   lines   stably   expressing   αIIbβ338-­40  
demonstrated  that  RAP1  mediates  integrin  activation  by  targeting  the  cytoskeletal  protein  
TALIN  to  the  plasma  membrane.  To  test  whether  RAP1  is  essential  for  TALIN-­mediated  
integrin   activation,   we   next   compared   Rap1a/b-­mKO   and   Talin1-­mKO   platelets31.  
Consistent   with   previous   reports31,41,42,   both   agonist-­induced   JON/A-­PE   binding   and  
aggregation   response  were   virtually   abolished   in  Talin1-­mKO   platelets   (Figure   3A,B).  
When  compared  to  Talin1-­mKO  platelets,  Rap1a/b-­mKO  platelets  exhibited  a  small  but  
significant   increase   in  JON/A-­PE  binding  and  delayed  aggregation   in   response   to  high  
doses  of  agonists  (except  ADP).  The  maximum  extent  of  aggregation  was  always  reduced  
in  Rap1a/b-­mKO  platelets  when  compared  to  control  platelets  and  aggregates  of  Rap1a/b-­
mKO  platelets  appeared  smaller  by  visual  inspection  (not  shown).  Residual  aggregation  
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of   Rap1a/b-­mKO   platelets   was   inhibited   by   pre-­incubation   with   a   function   blocking  
antibody  to  murine  αIIbβ3  (Figure  3B).  Thus,  while  Talin1-­mKO  platelets  were  intrinsically  
incapable  of  activating  αIIbβ3  integrin,  a  limited  amount  of  integrin-­mediated  aggregation  
was  observed  in  platelets  lacking  RAP1A  and  RAP1B.    
Platelets  also  express  all  RAP2  isoforms,  RAP2A,  RAP2B  and  RAP2C6-­8,  which  are  under  
the  control  of  the  same  GEF23  and  are  70%  homologous  to  RAP143.  Thus,  we  investigated  
whether   RAP2   GTPases   could   be   responsible   for   the   RAP1-­independent,   TALIN1-­
dependent  integrin  activation  elicited  by  high  doses  of  agonists  in  Rap1a/b-­mKO  platelets.  
We  stimulated  Rap1a/b-­mKO,  Talin1-­mKO  and  control  platelets   for  5  minutes  with  two  
distinct  concentrations  of  agonist,  above  or  below  the  aggregating  threshold  of  Rap1a/b-­
mKO  platelets,  and  then  measured  RAP2-­GTP  levels  in  these  samples  (Figure  3C).  We  
detected  comparable  levels  of  active  RAP2  in  platelets  from  all  genotypes.  Moreover,  we  
found   no   correlation   between   RAP2   activation   and   the   level   of   platelet   aggregation  
reached   by   these   platelets,   i.e.   RAP2   was   activated   in   both   aggregating   and   non-­
aggregating  platelets.  Thus,  it  is  unlikely  that  RAP2  signaling  mediates  integrin  activation  
in  platelets  deficient  in  RAP1.  
  
Loss  of  both  RAP1A/B  isoforms  impairs  platelet  spreading  and  clot  contraction  
Following   inside-­out   activation   of   αIIbβ3   integrin,   ligand   binding   triggers   outside-­in  
signaling  which  plays  an  essential  role  in  platelet  spreading  and  clot  contraction  by  linking  
integrin  activation  with  cytoskeletal  mechanical  forces44.  Previous  work  has  reported  that  
fibrinogen  binding  induces  RAP1  GTP-­loading25,  and  that  Rap1b-­/-­  platelets  exhibit  defects  
in  spreading24,25  and  clot  contraction25.    To  analyze  the  ability  of  our  RAP  mutant  platelets  
to  spread,  cells  were  added  to  fibrinogen-­coated  wells,  activated  with  ADP  at  37ºC,  and  
both  the  platelet  area  and  the  percentage  of  fully  spread  platelets  were  quantified.  Under  
these   conditions,   approximately   85-­90%   of   control   platelets   were   fully   spread.   Both  
Rap1a-­mKO   and   Rap1b-­mKO   platelets   spread   normally   compared   to   controls,   while  
Rap1a/b-­mKO  platelets  had  ~50%  reduction  in  platelet  area  and  displayed  an  abnormal,  
non-­spread   morphology   (Figure   3D).   Clot   contraction   was   also   partially   impaired   in  
Rap1a/b-­mKO  platelets  (Figure  3E).   In  both  the  platelet  spreading  and  clot  contraction  
assays,  the  defect   in  Rap1a/b-­mKO  platelets  was   less  severe   than   that  of  Talin1-­mKO  
platelets.      
  
Specific  RAP  isoforms  differentially  regulate  the  release  of  second-­wave  mediators.  
Deficiency  in  CalDAG-­GEFI  affects  not  only  platelet  integrin  activation  but  also  the  release  
of   second   wave   mediators17,19,20,23,   which   are   crucial   for   full   platelet   activation   and  
hemostatic   plug   formation.   Therefore,   we   next   investigated   the   contribution   of   RAP1  
isoforms   to   granule   secretion   and   TxA2   generation.   As   previously   described   for  
conventional   Rap1b-­KO   mice25,   RAP1B   deficiency   in   platelets   impaired   α-­granule  
secretion   in   response   to   GPVI,   but   not   PAR4   receptor   stimulation   (Figure   4A,B).   In  
contrast,  deletion  of  Rap1A  alone  did  not  affect  P-­selectin  exposure,  and  Rap1a/b-­mKO  
platelets  displayed  the  same  secretion  phenotype  as  Rap1b-­mKO  platelets.  Our  previous  
studies  suggested  important  cross-­talk  between  RAP1  and  RAC1  in  the  regulation  of  actin  
dynamics  and  granule  secretion   in  platelets  activated  via  GPVI23.  Consistently,  Rap1b-­
mKO  and  Rap1a/b-­mKO  platelets,  but  not  Rap1a-­mKO  platelets,  failed  to  activate  RAC1  
in  response  to  convulxin  stimulation  at  early  time  points  (Figure  4C,D).  RAC1-­GTP  levels  
were   also   significantly   reduced   in  Rap1a/b-­mKO   platelets   at   the   later   time   point   after  
addition  of  the  agonist.    
Our   previous   studies   also   demonstrated   impaired   TxA2   generation   in   platelets   lacking  
CalDAG-­GEFI19.   Consistently   we   found   that   both   RAP1   isoforms   contributed   to   TxA2  
generation,  with  Rap1b-­mKO  platelets  displaying  a  phenotype  almost  comparable  to  that  
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of  the  Rap1a/b-­mKO  platelets  and  RAP1A  playing  a  minor  role  (Figure  4E).    However,  
while   simultaneous   loss   of   both   RAP   stimulatory   pathways   (Caldaggef1-­/-­P2y12-­/-­)  
completely   blocked   GPVI-­mediated   TxA2   generation,   the   defect   in   this   response   was  
partially   overcome   in   Rap1a/b-­mKO   platelets   stimulated   with   a   high   concentration   of  
agonist  (Figure  4F).    
  
RAP1A  and  RAP1B  are  critical  for  platelet  adhesion  under  shear  conditions  and  the  
formation  of  both  thrombotic  and  hemostatic  plugs.    
To   assess   the   contribution   of   RAP1A   and   RAP1B   to   thrombus   formation   under  
physiological  shear  stress  conditions,  we  next  studied  platelet  adhesion  to  collagen  ex  
vivo   in   a  microfluidics   chamber  assay   (Figure  5A).  Under   these   conditions,   combined  
deficiency   of   RAP1A   and   RAP1B   strongly   inhibited   platelet   adhesion   to   collagen   and  
completely   prevented   platelet-­platelet   cohesion   (Figure   5B,C).   Expression   of   a   single  
Rap1a   allele   significantly   improved   platelet   adhesion   compared   to   the  Rap1a/b-­mKO  
platelets,  and  it  allowed  for  the  formation  of  few  very  small  thrombi.  Both  platelet  adhesion  
and  platelet-­platelet  cohesion  were  further  improved  in  blood  from  mice  expressing  only  a  
single  copy  of  Rap1b,  confirming  that  RAP1B  is  more  effective  than  RAP1A  in  supporting  
integrin-­mediated  platelet  adhesion.    
Consistent   with   the   ex   vivo   studies,   we   observed   severely   reduced   thrombotic   plug  
formation  after   ferric  chloride   injury   to  the  carotid  artery   in  Rap1a/b-­mKO  mice   (Figure  
5D).  No  defect  in  arterial  thrombosis  was  observed  in  Rap1a-­mKO  mice,  while  a  small  but  
significant  prolongation  in  the  occlusion  time  was  observed  in  Rap1b-­mKO  mice.    Thus,  
both  RAP1A  and  RAP1B  contribute  to  platelet  adhesion  and  thrombus  formation  under  
flow  conditions  ex  vivo  and  in  vivo.  
To  determine  the  contribution  of  individual  RAP1  isoforms  to  hemostatic  plug  formation  in  
vivo,  we  challenged  our  Rap1  knockout  mice  in  the  standard  tail  transection  model  (Figure  
6A,B)   and   our   recently   developed   laser   injury-­induced   saphenous   vein   hemostasis  
model35(Figure   6C,D).  While   expression   of   a   single   allele   of  Rap1b   was   sufficient   to  
promote  hemostasis  in  both  models,  a  significant  prolongation  in  the  bleeding  time  and  an  
increase  in  the  blood  loss  volume  from  the  severed  tail  were  observed  in  mice  expressing  
one  allele  of  Rap1a  and  in  Rap1a/b-­mKO  mice  (Figure  6A,B).  Interestingly,  only  Rap1a/b-­
mKO  showed  a  significant  increase  in  the  bleeding  time  after  laser  injury,  comparable  to  
that  observed  in  Talin1-­mKO  mice  (Figure  6C).  Compared  to  the  tail  transection  model,  
laser–induced   injuries   to  the  endothelial   lining  are  small   (~50µm   in  diameter).  Platelets  
expressing  one  allele  of  Rap1b  were  able  to  plug  these  small  lesions,  but  platelet  plugs  
were  significantly  smaller  than  in  control  mice  (Figure  6D  and  supplementary  videos).  
In  conclusion,  these  ex  vivo  and  in  vivo  studies  demonstrate  that  signaling  by  RAP1A  can  
partially  compensate  for  loss  of  RAP1B  during  hemostatic  and  thrombotic  plug  formation.    
  
RAP1   GTPases,   but   not   TALIN,   play   a   minor   role   for   embryonic   vascular  
development  and  vascular  integrity  at  sites  of  inflammation  in  the  adult.  
In   addition   to   their   classical   role   in   the   prevention   of   excessive   blood   loss   at   sites   of  
mechanical  injury,  platelets  also  safeguard  vascular  integrity  during  development  and  at  
sites   of   inflammation45-­47.   To   test   whether   platelet   RAP1-­TALIN   signaling   is   important  
during  development,  we  studied  embryos  from  Rap1a/b-­mKO  and  Talin1-­mKO  mice  for  
signs   of   blood-­lymphatic   mixing   (BLM).   Compared   to   controls,   ~E16.5  Rap1a/b-­mKO  
embryos  showed  very  mild  signs  of  BLM  as  shown  by  macroscopic  observation  of  whole  
embryos   and   immunostaining   of   embryo   sections   (Figure  7A).  Markedly  more   severe  
BLM  was  observed  in  some  Talin1-­mKO  embryos,  while  others  showed  only  mild  defects.  
Similar  to  our  observations  in  the  developing  embryos,  Talin1-­mKO  mice,  but  not  Rap1a/b-­
mKO  mice,  exhibited  significant  hemorrhage   in  a  model  of   immune  complex–mediated  
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inflammation  in  the  skin  (rpA  reaction)  (Figure  7B).  Hemorrhage  at  sites  of  inflammation  
in   Talin1-­mKO   mice,   however,   was   significantly   less   than   in   control   mice   rendered  
thrombocytopenic  (<2%  platelet  count).    
  
Discussion  
Integrin  inside-­out  activation  is  critical  for  platelet  adhesion  and  hemostatic  plug  formation  
at  sites  of  vascular   injury.  The  dogma  in  the  field   is  that   integrin  activation  requires  the  
assembly  of  the  integrin  activation  complex,  including  RAP1,  TALIN1,  and  KINDLIN3,  at  
the  cytoplasmic  tail  of  the  integrin  β  subunit48.  However,  while  platelet  integrin  activation  
was  completely  abolished  in  mice  deficient  in  Talin131,41  or  Kindlin349,  studies  in  germline  
knockout  mice  identified  a  significant,  but  not  crucial  role  for  RAP1B  in  this  process24,25.  
This   led   to   the   belief   that   there   is   a   RAP1-­independent   mechanism   that   facilitates  
TALIN/KINDLIN3-­mediated   integrin  activation   in  platelets50.  Alternative  mechanisms   for  
RAP1-­independent   TALIN   recruitment   in   proximity   of   the   integrin   were   suggested,  
including  TALIN  binding  to  acidic  phospholipids51.  Recent  advances  in  proteomic  profiling,  
however,  demonstrated  that  murine  platelets  also  express  ~20,000  RAP1A  molecules52,  
a  copy  number  that  may  be  high  enough  to  facilitate  integrin  activation  in  the  absence  of  
RAP1B.  Our  studies  in  mice  lacking  Rap1a  and/or  Rap1b  in  the  megakaryocytic  lineage  
provide  the  first  definitive  proof  that  both  RAP1A  and  RAP1B  regulate  the  activation  of  
αIIbβ3  and  β1  integrins  in  platelets.  Consistent  with  previous  reports24,  integrin  activation  
in  platelets  from  Rap1b-­mKO  mice  was  reduced  by  >50%.  However,  we  also  observed  a  
significant  contribution  of  RAP1A  to  β1  and  β3  integrin  activation  in  stimulated  platelets,  
which  accounted  for  >70%  of  the  integrin  activation  observed  in  platelets  lacking  RAP1B.  
The   residual   integrin  activation  observed   in  platelets   from  mice  deficient   in  both  RAP1  
isoforms  allowed  for  limited  platelet  aggregation  as  measured  in  standard  aggregometry.  
We  and  others  described  similar  results  for  mice  expressing  low  levels  of  CalDAG-­GEFI34,  
mice  expressing  a  loss-­of-­function  (LOF)  mutant  of  TALIN142,  or  mice  expressing  a  LOF  
mutant  of  KINDLIN353.  Our  studies  suggest  that  the  minimal  integrin  activation  observed  
in  Rap1a/b-­mKO  platelets  is  not  mediated  by  other  RAP  proteins,  as  RAP1-­independent  
platelet   aggregation  did  not   correlate  with  RAP2  activation.  Future   studies  will   have   to  
determine   whether   small   GTPase-­dependent   or   -­independent   mechanisms   mediate  
limited   integrin   activation   in   the   absence   of   RAP1   proteins.   Irrespective   of   the   exact  
mechanism,   however,   the   patho-­physiological   significance   of   this   RAP1-­independent  
pathway  of   integrin  activation   in  arterial   thrombosis  and  classical  hemostasis   is   limited  
considering  that  thrombus  formation  under  physiological  flow  conditions  was  abolished  in  
Rap1a/b-­mKO  mice.  Our   data   indicates   that   expression   of   at   least   one  Rap1   allele   is  
necessary  to  allow  for  the  minimal  amount  of  integrin  activation  that  supports  the  formation  
of  three-­dimensional  hemostatic  plugs  capable  of  ensuring  hemostasis.  While  expression  
of  a  single  Rap1b  allele   in  mice  was  sufficient   to   facilitate  hemostasis  at  sites  of  small  
(laser  injury)  and  large  injuries  (tail-­clip),  expression  of  a  single  Rap1a  allele  could  only  
support  hemostatic  plug  formation  after  small  injuries.  At  the  moment,  it  is  not  clear  how  
RAP1A  and  RAP1B  mediate  platelet  integrin  activation.  It  was  suggested  that  the  RAP1  
effector   RIAM   was   necessary   to   connect   RAP1   and   TALIN,   thereby   enabling   the  
recruitment  of  TALIN   to   the  plasma  membrane  where  active  RAP1   is   localized40.  This  
hypothesis   was   disproved,   however,   as   RIAM  was   found   dispensable   for   β1   and   β3  
integrin   activation,   adhesion   and   aggregation   of   murine   platelets54,55.      Recent   in   vitro  
studies   suggest   that   active   RAP1   can   directly   bind   TALIN56,   without   an   intermediate  
effector,  but  whether  this  is  true  also  in  platelets  needs  to  be  confirmed.  
  
Our  studies  also  provide  indirect  evidence  for  non-­overlapping  roles  of  RAP1A,  RAP1B  
and  RAP2  in  platelet  activation  (Supplementary  Figure  2).  While  both  isoforms  exhibit  
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redundant  function  in  integrin  activation  and  TxA2  formation,  RAP1B  primarily  facilitates  
cross-­talk  with  RAC1  and  solely  regulates  α-­granule  secretion  in  platelets  stimulated  via  
the  collagen  receptor,  GPVI.  Interestingly,  TxA2  formation  was  not  completely  abolished  
in   Rap1a/b-­mKO   platelets   as   it   was   in   platelets   lacking   CalDAG-­GEFI   and   P2Y12,  
pathways  that  control  the  activity  state  of  both  RAP1  and  RAP223.  Consistent  with  a  role  
for  RAP2  in  this  process,  proteomics  profiling6,52  revealed  that  platelets  express  several  
RAP2-­specific  effectors57,58,  including  MINK1.  Platelets  from  mice  deficient  in  MINK1  are  
defective   in   ERK   and   p38   MAPK   signaling59,   pathways   that   contribute   to   TxA2  
generation60.  Thus,  while  RAP2  does  not  seem  to  be  involved  in  the  regulation  of  integrin  
activation,   it   is   a   likely   player   in   the   regulation   of   MAPK-­dependent   TxA2   generation.  
Alternatively,   TxA2   production   may,   in   part,   depend   on   a   RAP-­independent   signaling  
pathway.  Rap1a/b-­mKO  platelets,  but  not  Rap1a-­mKO  and  Rap1b-­mKO  platelets,  were  
also  defective  in  cellular  responses  depending  on  integrin  outside-­in  signaling.  Our  data  
on   the  Rap1b-­mKO   platelets   is   not   consistent  with   previous   work   showing   defects   in  
outside-­in  signaling  in  platelets  from  Rap1b-­/-­  mice25.  Aside  of  methodological  differences,  
we  currently  do  not  have  an  explanation  for  the  conflicting  phenotypes.  It  is  also  important  
to   remember   that   integrin   inside-­out   activation   has   to   precede   outside-­in   signaling   in  
spreading  and  clot  contraction  assays.  Both  Rap1a-­mKO  and  Rap1b-­mKO  platelets,  but  
not  Rap1a/b-­mKO  platelets,  showed  robust  inside-­out  activation  of  aIIbb3  integrin.  Thus,  
the   defect   in   spreading   and   clot   contraction   observed   in  Rap1a/b-­mKO   platelets   may  
primarily  be  a  reflection  of  impaired  integrin  activation  in  these  cells.  Consistent  with  this  
conclusion,  Rap1b-­mKO  platelets  exhibited  a  defect  in  RAC1  activation  at  an  early  time  
point  after  agonist  stimulation,  while  no  defect  was  seen  later   in  the  activation  process.  
RAC1   activation   was   markedly   diminished   in   Rap1a/b-­mKO   platelets   throughout   the  
activation  process.    These  findings  could  be  explained  by  normal  outside-­in  signaling  in  
RAP1  mutant  platelets.  More  in-­depth  studies  will  be  required  to  clarify  this  point.  
  
While  well-­established   in  platelets,   surprisingly   little   is   known  about   the   contribution  of  
RAP   GTPase   signaling   to   megakaryocyte   development   and   platelet   production.   It   is  
known   that   ERK   is   activated   in   response   to   megakaryocyte   stimulation   with  
thrombopoietin,   a   key   cytokine   regulator   of   megakaryocyte   development61,62,   and   that  
RAP   and   RAS   GTPases   mediate   ERK   activation   in   megakaryocyte   cell   lines   via  
engagement  of  their  downstream  effectors  B-­RAF  and  RAF-­163,64.  While  mice  deficient  in  
RAF-­1   did   not   show   defects   in   megakaryocyte   biology65,   deficiency   in   B-­RAF   led   to  
impaired   hematopoietic   progenitor   cell   development   and   altered   megakayopoiesis66.  
Furthermore,  the  cross-­talk  between  RAP1  and  RAC1  may  also  affect  platelet  production,  
as  RAC1  is  an  important  regulator  of  proplatelet  formation  in  mature  megakaryocytes67.  
Deletion  of  RAC1   in  mice,  however,  did  not  affect   the  peripheral  platelet  count,  unless  
another  Rho  GTPase,  CDC42,  was  also  deleted.  Previous  preclinical  and  clinical  data  did  
not  suggest  a  role  for  RAP  in  megakaryocyte  biology  as  deficiency   in  CalDAG-­GEFI  or  
RAP1B   did   not   affect   the   peripheral   platelet   count   in   mice,   dogs,   or   humans17,20,24,68.  
Consistent   with   these   findings,   a   normal   platelet   count   was   observed   in   mice   with  
megakaryocyte-­specific   deficiency   in  Rap1a   or  Rap1b.  However,  Rap1a/b-­mKO  mice  
exhibited   a   significant   macrothrombocytopenia   and   a   marked   defect   in   proplatelet  
formation   in  vitro.   Thus,  we  here  provide   the   first   definitive  proof   that  RAP   is  a   critical  
player  during  platelet  production.  Studies  in  progress  will  address  if  RAP1A  and  RAP1B  
have  redundant  or  unique  functions  during  megakaryocyte  development  and  proplatelet  
formation.  Given  its  crucial  role  in  platelet  function,  it  is  surprising  that  CalDAG-­GEFI  is  
dispensable  in  megakaryocytes.  However,  while  RAP1  activation  in  platelets  depends  on  
a  highly  sensitive  and  rapidly-­activated  GEF  like  CalDAG-­GEFI,  megakaryocytes  do  not  
depend  on  the  same  kinetics  of  cellular  activation.  Future  studies  should  investigate  the  
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role  of  other  RAP-­GEFs,  such  as  PDZ-­GEF  and  EPAC,  as  regulators  of  RAP  signaling  in  
megakaryocytes.    
  
In  addition   to   their   role   in   thrombus   formation   at   sites  of   injury,   platelets   contribute   to  
hemostasis   by   ensuring   vascular   integrity   where   the   endothelial   barrier   has   been  
breached   without   mechanical   injury,   for   instance   during   development   or   at   sites   of  
inflammation   in  adulthood69.   In  both   cases   it   is   currently  not   clear  how  platelets  affect  
vascular   integrity.  However,  previous  studies   identified  mechanistic  similarities  as  mice  
with   defects   in   platelet   ITAM   signaling   show  BLM   during   embryonic   development  and  
marked  hemorrhage  at  sites  of  inflammation36,47,70-­72.  No  bleeding  was  observed  in  mice  
with  defects  in  receptors  and  signaling  molecules  important  for  classical  hemostatic  plug  
formation,   including  PAR   and  P2Y   receptors,  GPIb-­V-­IX,  αIIbβ3,   and  CalDAG-­GEFI47.  
Interestingly,   degranulated   platelets   failed   to   prevent   tumor-­associated   inflammatory  
bleeding73,  suggesting  that  granule  release  but  not  integrin-­mediated  adhesion  is  critical  
for   vascular   integrity   in   inflammation   and   during   development,   a   conclusion   that   was  
recently  challenged  by  studies  in  mice  genetically  engineered  to  be  defective  in  granule  
secretion74.  The  studies  reported  here  shift  the  focus  back  on  integrins,  as  we  observed  
significant   BLM   and   inflammatory   bleeding   in   Talin1-­mKO   mice.   However,   vascular  
integrity  was  intact   in  Rap1a/b-­mKO  mice.  Considering  this  partial  TALIN1  dependency  
and  recent  studies  demonstrating  that  single  platelets,  not  platelet  aggregates,  plug  holes  
in   the   inflamed   vascular   wall72,   we   propose   that   integrins   other   than   αIIbβ3   or   other  
TALIN1-­regulated   adhesion   receptors   contribute   to   platelet   adhesion   in   this   form   of  
hemostasis.   The   very   limited   ability   of   Rap1a/b-­mKO   platelets   to   activate   integrin  
receptors,   however,   seems   sufficient   to   prevent   hemorrhage   during   embryonic  
development   and   inflammation.   Alternatively,   it   is   possible   that   TALIN1   has   RAP1-­
independent  functions  that  are  critical  for  platelet-­mediated  vascular  integrity.  
  
In  humans,  loss-­of-­function  mutations  in  CalDAG-­GEFI20,21,75-­77  or  P2Y1278,  the  main  RAP  
stimulating  pathways,   lead   to  a  marked  defect   in  hemostasis.   Interestingly,  no  patients  
with  mutations  in  one  of  the  RAP1  isoforms  have  been  identified  to  date.  Studies  in  RAP1  
mutant  mice24  suggested  that  loss-­of-­function  in  Rap1b  may  cause  embryonic  lethality  in  
humans,  while  mutations  in  Rap1a  would  be  without  significant  impact  on  platelet  function  
and  hemostasis.  It  is  important,  however,  that  RAP1A  is  much  more  abundant  in  human  
than   in   mouse   platelets,   with   the   expression   ratio   for   RAP1B   to   RAP1A   being   2/1   in  
humans6  and  10/1  in  mice52.  Our  findings  of  functional  redundancy  between  the  two  RAP  
isoforms   in   the   inside-­out   activation   of   platelet   integrins   provides   an   alternative,   more  
plausible  explanation  for  the  lack  of  loss-­of-­function  mutations  in  either  Rap1a  or  Rap1b  
in  humans.  We  propose  that  both  isoforms  would  have  to  be  defective  simultaneously  for  
classical  hemostasis  to  be  impaired.  The  same  conclusions  can  be  drawn  for  the  role  of  
RAP1  in  platelet  production  and  the  effect  of  RAP1  mutations  on  the  peripheral  platelet  
count.  Lastly,  our  findings  also  have  important  implications  for  the  development  of  novel  
antiplatelet  therapies,  as  targeting  of  the  pathways  regulating  RAP1  activity  or  of  individual  
RAP1   isoforms   would   be   expected   to   provide   significant   protection   from   thrombosis  
without  jeopardizing  the  platelet  count  or  hemostasis.      
  
In   conclusion,   our   studies  demonstrate   that  RAP1  GTPases  have  both   redundant  and  
isoform-­specific  functions  in  platelets  and  MKs.  Mice  deficient  in  both  Rap1a  and  Rap1b  
exhibit  significant  macrothrombocytopenia  due  to  impaired  proplatelet  formation,  strongly  
impaired   integrin   activation   in   platelets,   and   marked   defects   in   hemostasis   after  
mechanical  injury.  In  contrast,  platelet  RAP1  signaling  is  dispensable  for  the  maintenance  
of  vascular  integrity  during  development  and  at  sites  of  inflammation  in  mice.    
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Figure  1.  Megakaryocyte-­specific  deletion  of  the  Rap1a  and  Rap1b  genes  leads  to  
macrothrombocytopenia.  Flow  cytometric  analysis  of   the  (A)  peripheral  platelet  count  
and  (B)  platelet  size  (forward  scatter  height,  FSH)  in  mice  lacking  one  or  both  alleles  of  
the  Rap1a  and  Rap1b  genes   in   the  platelet/megakaryocyte   lineage  as   indicated  below  
each  column  (n=12).  (C)  Platelet  lifespan  assay.    Endogenous  platelets  were  labeled  by  
infusion  of  Alexa  Fluor  488–conjugated  antibody  to  GPIX,  and  the  percentage  of  GPIX-­
labeled  platelets  remaining  was  determined  by  flow  cytometry  every  24  hours.  (D)  In  vitro  
pro-­platelet  (PP)  formation  in  bone  marrow–derived  megakaryocytes.  (E)  Representative  
images  of  megakaryocytes  for  PP  formation  assay,  acquired  on  an  Olympus  IX-­81  wide-­
field   microscope   with   a   Photometrics   CoolSnap   HQ2   camera.   *p<0.05,   **p<0.01,  
***p<0.001.  
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Figure  2.  Both  RAP1A  and  RAP1B  contribute   to  platelet   integrin  activation.   Flow  
cytometric  analysis  of  (A)  integrin  αIIbβ3  activation  (binding  of  Jon/A-­PE,  clone  Leo.H4,  
Emfret  Analytics)  and  (B)  integrin  β1  activation  (binding  of  9EG7-­FITC,  BD  Biosciences)  
in  response  to  increasing  concentrations  of  thrombin,  the  GPVI-­agonist  convulxin,  or  the  
combination  of  ADP  and  the  thromboxane  (Tx)A2  analog  U46619.  Data  shown  are  mean  
fluorescence  intensities  (MFI)  ±  SEM  of  control  (Rap1afl/flRap1bfl/flPf4-­Cre-­),  Rap1a-­mKO  
(Rap1afl/flRap1bwt/wtPf4-­Cre+),   Rap1b-­mKO   (Rap1awt/wtRap1bfl/flPf4-­Cre+)   and   Rap1a/b-­
mKO  (Rap1afl/flRap1bfl/flPf4-­Cre+)  platelets  (n  =  6);;  *p<0.05,  **p<0.01,  ***p<0.001.    
  
     
	   18	  
  
  
Figure   3.   Limited   TALIN1-­mediated   integrin   activation   in   platelets   lacking   both  
RAP1   isoforms   is   not  mediated   by  RAP2  GTPase.   (A)   Flow   cytometric   analysis  of  
αIIbβ3   integrin   activation   (JON/A-­PE   antibody   binding)   in   Rap1a/b-­mKO  
(Rap1afl/flRap1bfl/flPf4-­Cre+)  andTalin1-­mKO  (Talin1fl/flPf4-­Cre+),  platelets  (n=5);;  *p<0.05,  
***p<0.001.  (B)  Aggregation  response  of  platelets  from  Rap1a/b-­mKO  and  Talin1-­mKO  
platelets   (representative  of  4   independent  experiments).  For  high  dose  Par4p  and  Cvx  
aggregation,  the  residual  aggregation  response  of  Rap1a/b-­mKO  platelets  was  completely  
abolished  by  pre-­incubation  with  30  μg/ml  of   the  αIIbβ3  blocking  antibody  Leo.H4.   (C)  
Rap2-­GTP  pulldown  assay.  Washed  platelets  stimulated   (S)   in  standard  aggregometry  
with  0,  0.4  μg/mL  or  0.8  μg/mL  of  the  GPVI-­agonist  convulxin  (Cvx)  were  lysed  (L)  after  
10  minutes,  to  measure  the  levels  of  active  RAP2  by  pull-­down  assay;;  n=3.  Total  RAP2  
was  determined  as   loading  control.  (D)  Platelet  spreading  on  fibrinogen.  Platelets  were  
incubated   in   fibrinogen-­coated   wells,   activated  with   ADP   (100   µM),   and   the   extent   of  
platelet  spreading  was  determined  after  45  minutes.  Representative  images  of  phalloidin-­
stained  platelets  are  shown  (n=3-­5).  (E)  Clot  contraction  assay.    Washed  platelets  from  
indicated   knockout   mice   were   added   to   human   platelet-­poor   plasma   (PPP)   in   ACD  
containing  5  mM  Ca2+  and  0.2  U/ml  thrombin  in  siliconized  cuvettes  (n=3).  Representative  
images  of  clots  at   time  0  and  120  mins  are  shown;;   “no  platelets”  sample  contained  all  
components  except  washed  platelets.  *p<0.05,  **p<0.01,  ***p<0.001.  
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Figure  4.  Specific  RAP  isoforms  regulate  granule  secretion,  RAC1  activation  and  
TxA2  generation.  (A,  B)  Dose  response  studies  of  (A)  thrombin-­  or  (B)  convulxin-­induced  
P-­selectin   exposure   (anti-­CD62P   binding   by   flow   cytometry,   clone   RB40.34,   BD  
Biosciences).   Data   shown   are   mean   fluorescence   intensities   (MFI)   ±   SEM   of   control  
(Rap1afl/flRap1bfl/flPf4-­Cre-­,  black),  Rap1a-­mKO  (Rap1afl/flRap1bwt/wtPf4-­Cre+,  dark  grey),  
Rap1b-­mKO   (Rap1awt/wtRap1bfl/flPf4-­Cre+,   light   grey)   and   Rap1a/b-­mKO  
(Rap1afl/flRap1bfl/flPf4-­Cre+,  white)  platelets  (n=6).  (C,  D)  RAC1-­GTP  pulldown  assay.  (C)  
RAC1  activation  was  determined  by  pulldown  assay  in  platelets  of  the  indicated  genotype  
stimulated   for  0,  3  or  10  minutes  with  convulxin   (Cvx).  Total  RAC1  was  determined  as  
loading  control.    Western  blot  images  are  representative  of  3  independent  experiments.    
(D)  The  ratio  of  RAC1-­GTP  over  RAC1  band  intensity  for  the  three  experiments  is  shown  
as  fold  increase  over  resting.  (E,  F)  Thromboxane  (Tx)B2  generation  assay.  (E)  Washed  
platelets  from  control  (black  diamond),  Rap1a-­mKO  (dark  grey  circle),  Rap1b-­mKO  (light  
grey  square)  and  Rap1a/b-­mKO  (lighter  grey  triangle)  mice  were  stimulated  in  standard  
aggregometry  (not  shown)  with   low  doses  of  convulxin  (LD  Cvx;;  0.16  µg/ml).  After  0,  3  
and  10  minutes  of  stimulation  samples  were  withdrawn  to  measure  the  levels  of  TxB2,  the  
stable   product   of   TxA2.   (F)   In   similar   experimental   conditions,   Rap1a/b-­mKO   and  
Caldaggef1-­/-­P2y12-­/-­   platelets   were   stimulated   for   10  minutes   with   low   (LD   Cvx;;   0.16  
µg/ml)  or  high  (HD  Cvx;;  1.6  µg/ml)  doses  of  convulxin.  *p<0.05,  **p<0.01,  ***p<0.001.  
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Figure  5.  Both  RAP1A  and  RAP1B  are  critical  for  platelet  adhesion  and  thrombus  
formation  under  shear  conditions  ex  vivo  and  in  vivo.  (A,  B,  C)  Platelet  adhesion  to  
fibrillar  collagen  ex  vivo.  Anticoagulated  whole  blood  from  control  (Rap1afl/flRap1bfl/flPf4-­
Cre-­,   black),  Rap1afl/flRap1b+/flPf4-­Cre+   (green),  Rap1a+/flRap1bfl/flPf4-­Cre+   (orange)   or  
Rap1afl/flRap1bfl/flPf4-­Cre+   (red)   mice   was   perfused   over   fibrillar   collagen   type   I   (200  
μg/mL)  at  venous  shear  rates  (400-­s).  Adhesion  of  platelets  was  monitored  continuously.  
Shown  are  (A)  representative  images  after  5  minutes  of  perfusion  of  Alexa  Fluor  488–α-­
GPIX–labeled  platelets  obtained  on  a  Nikon  TE300   (Nikon,  Tokyo,   Japan)  microscope  
equipped   with   a   QImaging   Retiga   Exi   camera   (Qimaging,   Surrey,   BC,   Canada),   (B)  
platelet  adhesion  determined  as  the  area  of  adhesion  coverage  ±  SEM  and  (C)  thrombus  
buildup  quantified  as  sum  fluorescence  intensity  ±  SEM.  Analysis  were  performed  using  
Slidebook  5.0  Software  (Intelligent  Imaging  Innovations,  Denver,  CO).  (D)  FeCl3-­induced  
thrombosis  in  the  carotid  artery.  Data  shown  is  the  scatter  dot  plot  (line  at  median)  of  the  
time  of  occlusion  (minutes).  Blood  flow  velocity  was  monitored  for  30  minutes  with  a  0.5  
mm  Doppler  flow  probe  connected  to  a  TS420  Transonic  flowmeter  (Transonic,   Ithaca,  
NY);;   time   to   occlusion   was   recorded   when   blood   velocity   reached   25%   of   baseline  
velocity.  All  Rap1a/b-­mKO  vessels  never  dropped  below  25%  of  baseline  flow,  thus  they  
were  assigned  a  time  of  30  minutes.  *p<0.05,  **p<0.01,  ***p<0.001.  
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Figure   6.   Platelet   RAP1   signaling   is   critical   for   hemostasis   at   sites   of   injury.  
Determination  of  hemostasis  using  (A,  B)   tail  clip  or  (C,  D)  saphenous  vein   laser   injury  
model   in  control  (Rap1afl/flRap1bfl/flPf4-­Cre-­,  black  bar,  black   line),  Rap1afl/flRap1b+/flPf4-­
Cre+  (checkered  dark  grey  bars,  green  line),  Rap1a+/flRap1bfl/flPf4-­Cre+  (checkered  light  
grey  bars,   orange   line)   and  Rap1a/b-­mKO   (Rap1afl/flRap1bfl/flPf4-­Cre+,  white   bars,   red  
line)  mice.  Tail  bleeding  time  (A)  and  blood  loss  volume  (B)  was  determined  following  tail  
clipping.  (C)  Repeated  laser  injuries  were  made  to  the  saphenous  vein  using  an  Ablate!  
photoablation  system  equipped  with  an  attenuable  532nm  pulse  laser  (Intelligent  Imaging  
Innovations).  Bleeding  time  was  assessed  as  time   (seconds)  to  stable  hemostatic  plug  
formation  (no  leakage  of  blood  for  more  than  60  seconds)  within  the  laser  injury-­induced  
vascular   lesion.  Talin1-­mKO  mice   (Talin1fl/flPf4-­Cre+,   striped   bar),   which   bleed   for   the  
entire   observation   period,   are   shown   for   comparison.   (D)   Platelet   accumulation   was  
recorded  using  a  Zeiss  Axio  Examiner  Z1  microscope   (Intelligent   Imaging   Innovations,  
Denver,  CO)  equipped  with  a  20x/1  numerical  aperture  water   immersion  objective   lens  
and  determined  as  sum  fluorescence  intensity  (SFI)  of  GPIX-­labelled  platelets  ±  SEM  at  
the  site  of  injury  over  time;;  data  were  analyzed  using  Slidebook  5.0  software  (Intelligent  
Imaging  Innovations).  *p<0.05,  **p<0.01,  ***p<0.001.  
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Figure   7.   Platelet   RAP1   signaling   minimally   contributes   to   the   maintenance   of  
vascular  integrity  during  development  and  inflammation.  (A)  Contribution  to  vascular  
integrity  during  development  was  determined  by  assessing  blood/lymphatic  mixing  (BLM)  
in   embryos   at   ~E16.5   by  macroscopic   observation,   using   a   Leica  MZ16FA   dissecting  
stereoscope,   and   immunofluorescence   staining   of   embryos   sections.   Embryos   were  
sectioned  at   the   jugular   lymph  sac   (JLS)  and   lymphatic  endothelial   cells   (green)  were  
stained  with  primary  antibody,  polyclonal  rabbit  anti-­mouse  LYVE-­1    overnight,  followed  
by   donkey   anti-­rabbit   Alexa   Fluor   488      and   DAPI.      RBCs   were   visualized   by  
autofluorescence   (red).   Images   were   acquired   on   a   Nikon   E800   microscope   with   a  
Hammamatsu   camera   with   Metamorph   software   (Molecular   Devices   Corp.).   (B)  
Contribution   to   vascular   integrity   at   sites   of   inflammation   was   determined   by   reverse  
passive   Arthus   (rpA)   reaction   in   the   skin   of   control   (Pf4-­Cre-­)   mice   depleted   of   all  
circulating  platelets  (by  intravenous  injection  of  antibodies  against  GPIbα),  compared  to  
non-­depleted  Rap1a/b-­mKO  or  non-­depleted  Talin1-­mKO  mice.  Representative   images  
of  rpA  sites  are  shown  (indicated  by  dashed  outlines).  Hemorrhage  at  sites  of  inflammation  
was  quantified  by  measuring  hemoglobin   (Hb)   levels   in   skin   lesions  4   hours   after   rpA  
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